Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information

Omigapil maleate

EU orphan designation number: EU/3/08/544   
Active ingredient: Omigapil maleate
Indication: Treatment of congenital muscular dystrophy with merosin (laminin alpha 2) deficiency
Sponsor: Santhera Pharmaceuticals (Deutschland) GmbH
Marie-Curie Strasse 8, D-79539 Lörrach, Deutschland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
14/05/2008 Orphan designation EMEA/OD/009/08 (2008)1897 of 08/05/2008
28/05/2015 Change of name and/or address of sponsor
13/04/2016 Change of name and/or address of sponsor